Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay

Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produce vaccines and therapies globally. Thermo Fisher's business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augmen ...